Aragen Life Sciences Files Draft Papers With Sebi; Eyes Rs 800-Cr via Fresh Issue

New Delhi: Contract research, development and manufacturing organisation (CRDMO) Aragen Life Sciences Ltd has filed draft papers with capital markets regulator Sebi to raise Rs 800 crore through an initial public offering (IPO).

Apart from the fresh issue, there will be an offer for sale (OFS) of 2.73 crore equity shares by selling shareholders, according to the draft red herring prospectus (DRHP) filed on Wednesday.

The OFS comprises shares offered by both promoters and investor shareholders, including Goldman Sachs Capital Holdings.

Proceeds from the fresh issue will fund the repayment and/or pre-payment of borrowings, capital expenditure for purchasing new equipment and machinery at the company’s facilities in Hyderabad, and capital expenditure at its material subsidiary Aragen Biologics Pvt Ltd’s facility in Bengaluru. A portion of the proceeds will also be used for general corporate purposes.

Aragen Life Sciences, incorporated in 2000, is an integrated CRDMO serving global innovator companies and emerging firms across the life sciences industry. Its offerings span contract discovery and pre-clinical research as well as contract development and manufacturing services for small molecules and biologics.

The company served 591 global customers in fiscal 2026 across key markets, including the US, Europe, Japan, India and other Asia-Pacific markets. Its customers include big pharma companies, large and mid-sized pharmaceutical firms and biotechnology companies, in addition to players in animal health, agrochemicals and specialty chemicals.

Aragen’s workforce stood at 4,362 employees as of March 31, 2026.

Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities Pvt Ltd, and JM Financial are the book-running lead managers to the issue.

(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)